knowledge -WSS

knowledge

author：comprehensive 2025-09-30 18:08:14 - browse：6176

There’s a specter haunting Wall Street.

It started in biotech, where companies making drugs for the obesity-related liver disease NASH saw their valuations crash on the assumption that GLP-1 weight loss treatments would cut them out of the market. Then the Ozempic panic came for dialysis firms, whose stocks fell about 20% in a single day on the news that Novo Nordisk’s medicine had delayed the progression of kidney disease in a study enrolling people with type 2 diabetes.

Now analysts from every sector are cranking out research notes on the disparate, dramatic, and often debatable implications of GLP-1 drugs’ growing popularity, said Jared Holz, a health care specialist at Mizuho Securities. Buy Bumble, sell McDonald’s. Short Pepsi, go long Louis Vuitton. Put your money in sectors that cater to a svelte and sated brand of consumer, and get out of the ones that rely on excess and compulsion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： With psoriasis trial ahead, Alumis raises $259 million

knowledge

WSS

Biogen nominates mother of director’s child to replace him on board

A deep dive into Applied Therapeutics’ data, and questions on Cassava

A public health expert passes on football's full body collisions for youths

Inside the rise of 'mukbang' eating videos

Change Healthcare payments predicted restored March 15

NEJM study link tiny plastics in blood vessels to heart problems

hotspot

knowledge

explore

Hollywood unions extend contract negotiations for actors

Sen. Paul opposes bill to ban Chinese biotechs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Novo: Oral version of Ozempic leads to 15% weight loss

What does generative AI mean for health care? We asked experts

The thinking behind the controversial eating disorder chatbot Tessa

Medicare proposal to cover medical devices draws a mixed reaction

FDA approves first new drug developed for postpartum depression

Wildfire smoke exposes gaps in outdoor worker protections

Altering the blood type of lungs raises potential for universal organs for transplants

knowledge

Living organ donors deserve priority status for transplants

Biden administration plans revamp of organ transplant system

What it’s like to watch children die of measles

UnitedHealth quietly bought dozens of outpatient centers

Headspace, Meta partner to launch VR meditation app for Quest

With psoriasis trial ahead, Alumis raises $259 million

knowledge

explore

hotspot

leisure time